KRAS and lung cancer: A recent randomized trial demonstrated that the combination of bexarotene (the first RXR-selective retinoid) with/tivantinib (a MET inhibitor) and erlotinib is effective as a treatment for KRAS-mutation-driven lung cancer and is well-tolerated [55]–[56].